BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage...
MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel...
IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological...
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage...
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and...
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.